Systemic Lupus Erythematosus – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Systemic Lupus Erythematosus – Pipeline Review, H2 2020’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

– The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

– The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

ACEA Therapeutics Inc

Akeso Inc

Alexion Pharmaceuticals Inc

Alpine Immune Sciences Inc

Aluda Pharmaceuticals Inc

Amgen Inc

Apellis Pharmaceuticals Inc

Apimeds Inc

Aprilbio Co Ltd

APT Therapeutics Inc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Athos Therapeutics Inc

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

Avotres Inc

BellBrook Labs LLC

Bio-Path Holdings Inc

BioAegis Therapeutics Inc

Biocon Ltd

Biogen Inc

Biotest AG

BioTheryX Inc

Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Systemic Lupus Erythematosus - Overview

Systemic Lupus Erythematosus - Therapeutics Development

Systemic Lupus Erythematosus - Therapeutics Assessment

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

Systemic Lupus Erythematosus - Drug Profiles

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by ACEA Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Akeso Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Alexion Pharmaceuticals Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Alpine Immune Sciences Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Aluda Pharmaceuticals Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Amgen Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Apellis Pharmaceuticals Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Apimeds Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Aprilbio Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by APT Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp, H2 2020

Systemic Lupus Erythematosus – Pipeline by Astellas Pharma Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by AstraZeneca Plc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Athos Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Atlantic Bio Sci LLC, H2 2020

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Avotres Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by BellBrook Labs LLC, H2 2020

Systemic Lupus Erythematosus – Pipeline by Bio-Path Holdings Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by BioAegis Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Biocon Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H2 2020

Systemic Lupus Erythematosus – Pipeline by BioTheryX Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Systemic Lupus Erythematosus – Pipeline by Boston Pharmaceuticals Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Co, H2 2020

Systemic Lupus Erythematosus – Pipeline by Rheos Medicines Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Sanofi, H2 2020

Systemic Lupus Erythematosus – Pipeline by Sareum Holdings Plc, H2 2020

Systemic Lupus Erythematosus – Pipeline by SBI Biotech Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Sengenics Corp Pte Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Shanghai GeneChem Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by SinoMab Bioscience Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by StingInn LLC, H2 2020

Systemic Lupus Erythematosus – Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by SynAct Pharma AB, H2 2020

Systemic Lupus Erythematosus – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by TherapyX Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2020

Systemic Lupus Erythematosus – Pipeline by Twoxar Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by UCB SA, H2 2020

Systemic Lupus Erythematosus – Pipeline by Vera Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Viela Bio Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Visterra Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by Voronoi Group, H2 2020

Systemic Lupus Erythematosus – Pipeline by Xencor Inc, H2 2020

Systemic Lupus Erythematosus – Pipeline by XTL Biopharmaceuticals Ltd, H2 2020

Systemic Lupus Erythematosus – Pipeline by ZyVersa Therapeutics Inc, H2 2020

Systemic Lupus Erythematosus – Dormant Projects, H2 2020

Systemic Lupus Erythematosus – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports